Author

M. D. Blunt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Al-Shamkhani· 1 shared A. F. Vallejo· 1 shared A. J. Steele· 1 shared A. Russell· 1 shared A. W. E. Purcell· 1 shared B. Mbiribindi· 1 shared C. Goodnow· 1 shared C. Retiere· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Al-Shamkhani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL

D. Bryant, L. Smith, K. R. Rogers-Broadway, L. Karydis, J. Woo, M. D. Blunt, F. Forconi, F. K. Stevenson, C. Goodnow, P. Humberg, A. Russell, G. K. Packham, A. J. Steele, J. C. Strefford

The paper identifies 14q32 cluster miRNAs as key regulators of transcriptional differences between IGHV-mutated and unmutated CLL, with miR-409-3p and miR-411-3p repressing GAB1.

bioRxiv · Apr 26, 2022Cancer Biology

Peptide:MHC dependent activation of natural killer cells through KIR2DS2 generates anti-tumor responses

P. Rettman, M. D. Blunt, B. Mbiribindi, R. Fulton, R. Schittenhelm, A. F. Vallejo, L. Bastidas-Legarda, M. E. Polak, R. Ayala, A. W. E. Purcell, A. Al-Shamkhani, C. Retiere, S. I. Khakoo

This study shows that activating NK cells via KIR2DS2 with a peptide:MHC vaccine generates anti-tumor responses and identifies XPO1 as a cancer-associated ligand for KIR2DS2.

bioRxiv · Apr 15, 2020 · PreprintImmunology